State of Wyoming Boosts Holdings in Illumina, Inc. $ILMN

State of Wyoming raised its position in Illumina, Inc. (NASDAQ:ILMN) by 252.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,054 shares of the life sciences company’s stock after purchasing an additional 5,767 shares during the period. State of Wyoming’s holdings in Illumina were worth $765,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ILMN. WCM Investment Management LLC grew its position in Illumina by 5.9% during the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock worth $419,585,000 after buying an additional 247,460 shares in the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Illumina by 1.9% during the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after purchasing an additional 78,317 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Illumina by 55.3% in the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after purchasing an additional 1,174,295 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Illumina by 0.7% in the second quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after purchasing an additional 21,342 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Illumina by 1.9% in the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after purchasing an additional 35,167 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.17% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Robert W. Baird set a $109.00 price target on shares of Illumina in a report on Friday, October 31st. JPMorgan Chase & Co. raised their price target on Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. UBS Group upped their price objective on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Six investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $127.18.

Illumina Stock Performance

Shares of ILMN stock opened at $141.13 on Tuesday. The company has a market capitalization of $21.56 billion, a P/E ratio of 31.64, a PEG ratio of 2.40 and a beta of 1.45. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The stock has a 50 day moving average price of $138.39 and a two-hundred day moving average price of $115.46.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.